The Potential Impact of Investigational Therapies

EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer

EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer

EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer

EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer

EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer

EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing

EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer

EP: 8.The Role of Novel Targeted Therapies

EP: 9.The Use of PARP Inhibitors in Ovarian Cancer

EP: 10.Earlier Introduction of Antibody-Drug Conjugates

EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients

EP: 12.Single-Agent Vs Combination Regimens

Now Viewing

EP: 13.The Potential Impact of Investigational Therapies

EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer

EP: 15.Overcoming Payer-Related Barriers for Optimal Care in Patients With Ovarian Cancer

EP: 16.The Importance of Multidisciplinary Collaboration in the Management of Ovarian Cancer

Video content is prompted by the following: Future Potential of Novel Therapeutic Approaches

Key Discussion Points:

• TROP-2 ADCs
• Multiple TROP-2 ADCs in development, including sacituzumab govitecan and datopotamab deruxtecan

• Most require weekly or every-15-day dosing schedules vs 21-day dosing for other ADCs

• Clinical development decisions likely to be influenced by biomarker selection, toxicity profiles, and patient convenience factors
• Additional ADC Development
• Multiple targeted ADCs in clinical development (catherin-6, folate, claudin-6, B7H4)

• Next generation agents like IMGN-151 (biparatopic folate–targeted with different microtubule toxin)

• Selection criteria may shift toward safety and patient experience if efficacy appears similar
• Cellular Therapies
• Engineered T-cells showing more promise than CAR T in ovarian cancer

• CAR-NK cells potentially more promising than CAR T

• Manufacturing challenges include extended production time and patient selection issues

Notable Insights:

“CAR T, the limitation with ovary is that a lot of our proteins are intracellular proteins...but CAR-NK may be a completely different ballgame for us.”

“The challenge with [cellular therapies] is...you can’t leave people just sitting around for 2 months waiting for manufacture of cells who have kind of actively growing disease. It’s not ethical.”